Clinical trials: Contrast-Induced Nephropathy
Kidney Failure
Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization
The purpose of this study is to determine if patients should stop taking their angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) around the time of their angiogram in order to prevent contrast…
- Trial name
- NCT00317252
- Testing
- Hold ACEI or ARB
- Where
- Canada
- Volunteers
- 220 people
- Sponsor
- Hamilton Health Sciences Corporation
Contrast-Associated Acute Kidney Injury, Contrast-induced Nephropathy
Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED
This study is planned to be conducted by emergency physicians between November 7, 2025, and December 7, 2026. Inclusion and Exclusion Criteria The study will include adult patients aged 18 years and older who are considered at…
- Trial name
- NCT07459413
- Testing
- Water, %0,9 NaCl
- Where
- Turkey (Türkiye)
- Volunteers
- 198 people
- Sponsor
- Gaziosmanpasa Research and Education Hospital
Contrast Media Induced Nephropathy (CIN)
Neutrophil Gelatinase-associated Lipocalin (NGAL) and Contrast Media Induced Nephropathy
Introduction: Patients with pre-existing impaired renal function are prone to develop acute contrast media induced nephropathy (CIN).
- Trial name
- NCT01292317
- Testing
- application of intravenous volume, oral fluid application
- Where
- Austria
- Volunteers
- 819 people
- Sponsor
- Medical University of Graz
Contrast Induced Nephropathy
Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial
Biomarkers such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) have been used for the early diagnosis of AKI, although with no definitive results.
- Trial name
- ACTIN (NCT02650336)
- Testing
- contrast
- Where
- China
- Volunteers
- 592 people
- Sponsor
- Sun Yat-sen University
Contrast-Induced Acute Kidney Injury
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.
- Trial name
- NCT01146925
- Testing
- CRMD-001-Deferiprone
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- CorMedix Therapeutics
Nephropathy
Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy
Acute renal failure induced by radiographic contrast agents is a known complication of coronary angiography.hypoxia plays a major role in the pathogenesis of Contrast induced nephropathy.
- Trial name
- NCT01448889
- Testing
- 100% oxigen
- Where
- Israel
- Volunteers
- 180 people
- Sponsor
- Assaf-Harofeh Medical Center
Kidney Cancer
MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer
RATIONALE: Comparing results of MRI scans done after bevacizumab may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00873236
- Testing
- bevacizumab, recombinant interferon alpha-2a
- Where
- 5 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
Contrast Induced Nephropathy, Diabetes Mellitus
Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography
The investigators will study 2 separate groups: Cardiology patients undergoing invasive coronary angiography +/- PCI (Percutaneous coronary intervention). Patients undergoing CT examination with contrast medium.
- Trial name
- NCT01144091
- Testing
- pentoxyphylline, pentoxiphylline
- Sponsor
- Meir Medical Center
Acute Kidney Injury
Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects
Iodinated contrast media have been causally linked to acute kidney injury known as contrast-induced nephropathy (CIN), which is the consequence of CM-induced local renal ischemia and direct toxic effects.
- Trial name
- PROTECT (NCT02869347)
- Testing
- Conestat alfa, Sodium chloride 0.9%
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- University Hospital, Basel, Switzerland
Acute ST Segment Elevation Myocardial Infarction
Predictive Value of CHA2DS2VASC Score for Contrast-induced Nephropathy After Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction Patients
Contrast induced acute kidney injury has commonly been referred to as contrast induced nephropathy (CIN) defined as an increase in serum creatinine ≥25% or ≥0.5 mg/dl from baseline within 48-72 hours with peak incidence 2-5 days…
- Trial name
- NCT04730778
- Testing
- serum creatinine and estimated glomerular filtration rate, on daily basis
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Cairo University
Acute Kidney Injury
Effect of Darbepoetin in Contrast-induced Nephropathy
The purpose of this study is to determine whether the drug that produce red blood cells is effective in the prevention of kidney dysfunction after coronary angiography in patients with chronic kidney disease.
- Trial name
- NCT01197235
- Testing
- darbepoetin-α, isotonic saline
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Seoul National University Bundang Hospital
Renal Artery Stenosis
A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.
- Trial name
- NCT00209391
- Testing
- Gadodiamide Injection
- Where
- Germany
- Volunteers
- 395 people
- Sponsor
- GE Healthcare
Acute Kidney Injury, Contrast Media Reaction
PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization
Intravascular administration of iodinated contrast media is an essential tool for cardiovascular imaging and percutaneous coronary interventions.
- Trial name
- TEATE (NCT02980003)
- Testing
- isotonic saline, i.v. sodium bicarbonate, oral sodium bicarbonate
- Where
- Italy
- Volunteers
- 240 people
- Sponsor
- G. d'Annunzio University
Contrast Induced Nephropathy
Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients
The purpose of this study is to demonstrate the efficacy of alpha tocopherol for prevention contrast-induced nephropathy in CKD patients undergoing elective coronary procedures.
- Trial name
- NCT01061320
- Testing
- alpha tocopherol
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Thammasat University
Contrast-Induced Nephropathy, Acute Kidney Injury
Uric Acid to Albumin Ratio for Predicting Contrast Associated Acute Kidney Injury After Cardiac and Non Cardiac Procedures
Contrast-associated acute kidney injury (CA-AKI) is a potential complication that can occur following exposure to iodinated contrast media during diagnostic and interventional procedures, contributing to prolonged hospital stays…
- Trial name
- NCT07855653
- Volunteers
- 100 people
- Sponsor
- Assiut University
Contrast-induced Nephropathy
Mehran 2.0 Risk Score for Prediction of CA-AKI After PCI
Consecutive patients having percutaneous coronary intervention (PCI) over a period of 9 years at a large tertiary care center with available creatinine measurements both before and within 48 hours after the procedure were…
- Trial name
- NCT05132062
- Testing
- Percutaneous Coronary Intervention
- Where
- United States
- Volunteers
- 14,616 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Contrast Induced Nephropathy, Acute Renal Failure
Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients
Hypothesis: Cystatin C compared with creatinine is a better and earlier marker of contrast-induced nephropathy in high and intermedium risk cardiac catheterization patients.
- Trial name
- NCT00467311
- Where
- Mexico
- Volunteers
- 66 people
- Sponsor
- National Heart Institute, Mexico
Contrast-induced Nephropathy Following Percutaneous Intervention (CIN)
Efficacy and Safety of a Beet-Derived Inorganic Nitrate-Based Food Product for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Percutaneous Coronary Intervention
Contrast-induced nephropathy (CIN) is a common complication in high-risk patients undergoing percutaneous coronary intervention (PCI) due to exposure to iodinated contrast agents.
- Trial name
- BEET-CIN (NCT06984406)
- Testing
- Beet-Derived Inorganic Nitrate-Based Food Product
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Contrast Induced Nephropathy (CIN)
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN
The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).
- Trial name
- AVERT™ (NCT01976299)
- Testing
- AVERT
- Where
- 39 sites in United States, Australia and 1 more
- Volunteers
- 578 people
- Sponsor
- Osprey Medical, Inc
Percutaneous Coronary Intervention Patients
The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coronary Intervention
In our study, we aimed to investigate how whole blood viscosity (WBV) affects the development of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary intervention (PCI).
- Trial name
- NCT04703049
- Testing
- Blood Viscosity Testing
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Bursa Postgraduate Hospital